• Researchers have identified a new radioactive substance called CB-2PA-NT as a promising candidate for a theranostics strategy, combining therapy and diagnostics.
• The substance, which targets neurotensin receptors found in various cancers, demonstrates high uptake and retention in tumors while maintaining a clear distinction from surrounding tissues.
• With regulatory approval pending, researchers hope to conduct human imaging studies using CB-2PA-NT in the near future, which could impact personalized medicine for cancer patients.

By Paul Ian Cross, PhD on July 4, 2023 — Fact checked by Hannah Flynn

read full article